Is Erdafitinib available in regular domestic hospitals?

Erdafitinib is a targeted drug used to treat locally advanced or metastatic urothelial carcinoma with FGFR gene mutations. It has been officially approved for marketing in China. However, because it has been on the market for a short time in China and has not yet been included in the national medical insurance directory, it may be temporarily difficult to purchase the drug directly in regular hospital pharmacies in some cities or regions. If patients need medicine, they need to contact a hospital or designated pharmacy qualified for sales in advance to confirm whether the medicine is in stock or whether the medicine can be obtained through special channels.

Although erdafitinib is already on the market in China, some patients will still consider purchasing it from overseas channels due to its high price and the fact that it has not entered the medical insurance reimbursement system. Currently, the original erdafitinib drug supplied in the overseas market is mainly the Hong Kong version, with the same specifications and ingredients as the domestic version, and the price per box is as high as more than 20,000 yuan. Hong Kong pharmacies have relatively standardized drug management, but they need to be purchased with a doctor's prescription or through the assistance of a professional organization, so they are not suitable for all patients.

In addition, there are also generic versions of erdafitinib on the market, mainly from countries such as Laos and Bangladesh. For example, the prices of generic drugs produced by the Lao version and Bangladesh Yaopin International Pharmaceutical Company are more affordable, generally ranging from a few hundred yuan to more than 2,000 yuan. These generic drugs are usually basically the same as the original drugs in terms of main ingredients and therapeutic mechanisms, and are favored by many patients. However, it should be noted that when choosing generic drugs, patients should ensure that they come from regular sources to avoid medication risks caused by unclear purchase channels.

To sum up, although erdafitinib has been approved for marketing in China, it has not yet fully covered all major hospitals. It is recommended that patients consult local tertiary hospitals or oncology institutions to see if it is available before preparing to take the drug. At the same time, you can also consider obtaining drugs through overseas pharmacies or overseas generic drug channels, but you must pay attention to safety and compliance issues and use drugs rationally under the guidance of professional doctors.

Reference link:https://www.balversa.com/